ClinicalTrials.gg
CompletedNCT00069901Updated Sep 22, 2008

Phase II CT-2103/Carboplatin in Ovarian Cancer

A Phase 2 interventional study of CT-2103 (poly(L)glutamate-paclitaxel) and carboplatin in Ovarian Neoplasm, sponsored by CTI BioPharma. Completed at 17 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-09-22.

Sponsored by CTI BioPharma (part of Swedish Orphan Biovitrum) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
82
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 166 studies testing carboplatin in Ovarian Neoplasms — 14 open to participants now, 21 under way, 6 of them phase 3. Carboplatin · Ovarian Neoplasms.

Enrollment
47th of 150
82 · median 48
Started
2003
with 9 others
Phase 2
84 of 166
8 open now
Registered
43rd of 166
by date

Among the 166 studies testing carboplatin in Ovarian Neoplasms, this one is the 47th largest by enrollment of the 150 interventional ones that give a count, is one of 10 that started in 2003, is one of 84 in phase 2, and was the 43rd registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

14 of the 166 studies testing carboplatin in Ovarian Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carboplatin

Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 166 studies testing carboplatin in Ovarian Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of CT-2103 (poly(L)glutamate-paclitaxel) in combination with carboplatin for the treatment of patients with Stage III or IV ovarian or primary peritoneal cancer.

Read the detailed description

CT-2103 is a pharmaceutical that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer. The objective of this trial is to evaluate the toxicity, estimate the response rate, progression-free survival and overall survival in patients with newly diagnosed stage III or IV ovarian or primary peritoneal carcinoma treated with CT-2103 in combination with carboplatin.

03

Conditions studied

  • Ovarian Neoplasm

Browse trials for

Keywords

  • ovarian cancer
  • paclitaxel
  • carboplatin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -confirmed stage III or IV ovarian carcinoma or primary peritoneal cancer patients who have had appropriate debulking surgery for ovarian or peritoneal carcinoma.
  • Patients must be recovered from initial surgery and must enter this study no later than 12 weeks after such surgery.
  • performance score of 0, 1, or 2.
  • (ANC) at least 1,500/µL.
  • at least 100,000/µL.
  • at least 10 g/dL.
  • creatinine no greater than 1.5 times the (ULN).
  • no greater than 1.5 x ULN (if liver are not present, and SGPT no greater than 2.5 x ULN, if liver metastases are present, SGOT and SGPT may be no greater than 5 x ULN.
  • Alkaline phosphatase no greater than 2.5 x ULN.

Exclusion criteria

Exclusion:

  • Current diagnosis of epithelial ovarian tumor of low malignant potential (borderline carcinomas)
  • Germ cell tumors, sex cord-stromal tumors, carcinosarcomas, mixed mullerian tumors or carcinosarcomas, carcinomas from sites other than the ovary, and low malignant potential tumors including so called micropapillary serous carcinomas.
  • Synchronous primary endometrial cancer or history of primary endometrial cancer.
  • Evidence of any other invasive present within the 3 years before this study, with the exception of non-melanoma skin cancer and other specific malignancies as noted above.
  • Any prior treatment, other than initial debulking surgery, for the cancer being treated in this study.
  • Patients may have received prior chemotherapy for localized breast cancer, if the therapy was completed at least 3 years before registration in this study and if the patient remains free of recurrent or metastatic disease.
  • Prior radiotherapy to any portion of the abdominal cavity or pelvis.
  • Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, if it was completed at least 3 years before registration in this study and if the patient remains free of recurrent or metastatic disease.
  • Administration of other drugs within 26 weeks before the first treatment in this study. Toxic manifestations of previous treatments (except alopecia) must have been stable for 4 weeks.
  • Presence of active hepatitis, either acute or chronic.
  • Presence of active infection requiring antibiotic or antiviral therapy.
  • Pregnant women or nursing mothers.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
82 participants (actual)

Interventions

06

Study locations

17 sites
  • California Cancer Care
    Greenbrae, California 94904, United States
  • Gynecology Oncology Associates
    Greenbrae, California, United States
  • Stockton Hematology Oncology Medical
    Stockton, California 95204, United States
  • Raben and Fldman Research Associates
    South Miami, Florida 33143, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Resource Center for Gynecology/ Oncology
    Kansas City, Missouri 64132, United States
  • Upstate New York Cancer Research and Education Foundation
    Rochester, New York 98104, United States
  • Gynecology, Oncology, and Pelvic Surgery Associates, Inc.
    Columbus, Ohio 43222, United States
  • Albert Einstein Cancer Center
    Philadelphia, Pennsylvania 19141, United States
  • Guthrie Foundation for Education and Research
    Sayre, Pennsylvania 18840, United States
  • South Carolina Oncology Assoicates
    Columbia, South Carolina 29203, United States
  • Chattanooga GYN-Oncology
    Chattanooga, Tennessee 37403, United States
  • Baptist Regional Cancer Center
    Knoxville, Tennessee 37920, United States
  • Arlington Fairfax Hematology Oncology
    Arlington, Virginia 22205, United States
  • Pacific Gynecology Specialists
    Seattle, Washington 98104, United States
  • Swedish Cancer Institute
    Seattle, Washington 98104, United States
  • Aurora Health Care, Inc.
    Milwaukee, Wisconsin 53201, United States
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2003, a primary completion of Nov 2005 and a completion of Sep 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2003
First posted
Oct 6, 2003
Start
Feb 2003
Primary completionActual
Nov 2005
CompletionActual
Sep 2006
Last update
Sep 22, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00069901
Lead sponsor
CTI BioPharma
First posted
Oct 6, 2003
Start date
Feb 2003
Primary completion
Nov 2005
Completion
Sep 2006
Last update
Sep 22, 2008

Study contacts

Scott Stromatt, M.D.
study director · CTI BioPharma
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Paclitaxel poliglumex · Carboplatin

Start the discussion